```html

Neutrophilic Dermatoses – A Patient‑Friendly Medical Guide

Overview

Neutrophilic dermatoses (NDs) are a heterogeneous group of skin disorders characterised by an intense infiltration of neutrophils (a type of white blood cell) into the dermis and sub‑cutaneous tissue without an obvious infection. The most common entities include:

• Sweet’s syndrome (acute febrile neutrophilic dermatosis)
• Pyoderma gangrenosum (PG)
• Subcorneal pustular dermatosis (Sneddon‑Wilkinson disease)
• Erythema elevatum diutinum
• Behçet’s disease‑associated skin lesions (when neutrophils predominate)

These conditions can affect adults of any age, but most epidemiologic data point to a peak incidence between the fourth and sixth decades of life. Women are slightly more often affected by Sweet’s syndrome (≈ 3 : 2 female‑to‑male ratio) while pyoderma gangrenosum shows a more balanced gender distribution.<sup>[1][2]</sup>

Exact prevalence is difficult to determine because NDs are rare and often under‑diagnosed. Estimates suggest:

• Sweet’s syndrome – 2–5 cases per million per year.
• Pyoderma gangrenosum – 3–10 cases per million per year.
• Overall collective prevalence of neutrophilic dermatoses – roughly 1 in 100 000 individuals.

Symptoms

Because NDs encompass several distinct entities, the clinical picture varies. Below is a consolidated list of the most frequent skin and systemic manifestations, with brief descriptions.

Skin Findings

• Painful, erythematous papules or plaques – often tender, may have a “pseudovesicular” appearance (seen in Sweet’s syndrome).
• Violaceous or dusky‑red ulcers with undermined borders – classic for pyoderma gangrenosum; lesions expand peripherally and can be deep.
• Flaccid pustules on an erythematous base – typical of subcorneal pustular dermatosis; lesions may coalesce into annular plaques.
• Firm, brownish nodules or plaques – characteristic of erythema elevatum diutinum, often on extensor surfaces.
• Pathergy reaction – lesions that develop or worsen at sites of trauma (needles, minor scratches). Common in PG and Behçet’s disease.
• Scarring – especially after healing of deep PG ulcers; may lead to contractures.

Systemic Symptoms (most notable in Sweet’s syndrome)

• Fever (often >38 °C)
• Generalised malaise, arthralgia or myalgia
• Neutrophilia on complete blood count (CBC) – typically > 8 × 10⁹/L
• Elevated inflammatory markers (ESR, CRP)

Causes and Risk Factors

Neutrophilic dermatoses are considered auto‑inflammatory rather than autoimmune; the immune system erroneously activates neutrophils without a pathogen. Known triggers and associations include:

Underlying Systemic Diseases

• Hematologic malignancies – especially acute myeloid leukemia, myelodysplastic syndrome, and lymphoma (≈ 20 % of Sweet’s syndrome cases).
• Inflammatory bowel disease (IBD) – ulcerative colitis and Crohn’s disease are linked to PG in up to 30 % of patients.
• Rheumatic disorders – rheumatoid arthritis, seronegative spondyloarthropathies.
• Solid organ malignancies – breast, gastrointestinal, and genitourinary cancers.
• Pregnancy – a recognized trigger for Sweet’s syndrome.

Medication‑Related Triggers

• Granulocyte colony‑stimulating factor (G‑CSF) therapy.
• All‑trans‑retinoic acid (ATRA) used in acute promyelocytic leukemia.
• Thiazide diuretics, non‑steroidal anti‑inflammatory drugs (NSAIDs), and certain antibiotics (rare).

Other Risk Factors

• Genetic predisposition – polymorphisms in the MEFV gene (associated with familial Mediterranean fever) have been reported in some cases.
• Smoking – may increase risk of PG, especially in the context of IBD.
• Obesity – linked to higher incidence of PG after trauma or surgery.

Diagnosis

Diagnosing NDs is largely a process of exclusion: ruling out infection, vasculitis, malignancy, and other dermatoses. A systematic approach includes:

Clinical Evaluation

• Detailed history (onset, progression, associated systemic disease, medication exposure, trauma).
• Physical examination focusing on lesion morphology, distribution, and presence of pathergy.

Laboratory Tests

• Complete blood count (CBC) – neutrophilia is common.
• Inflammatory markers – ESR, CRP often elevated.
• Autoimmune panel – ANA, ANCA to exclude vasculitis when indicated.
• Serologies for HIV, hepatitis B/C if risk factors are present.

Skin Biopsy (Gold Standard)

A 4‑mm punch biopsy taken from an active lesion (preferably before systemic steroids) typically shows:

• Dense neutrophilic infiltrate in the upper dermis (Sweet’s syndrome).
• Leukocytoclastic debris, fibrinoid necrosis, and epidermal ulceration in PG.
• Subcorneal accumulation of neutrophils in Sneddon‑Wilkinson disease.

Special stains (Gram, PAS) help rule out bacterial, fungal, or mycobacterial infection.

Imaging (when indicated)

• Chest X‑ray or CT to search for underlying malignancy.
• Abdominal/pelvic imaging (ultrasound, CT, or MRI) when IBD or visceral organ involvement is suspected.

Treatment Options

Therapy is tailored to the specific ND, severity, and any associated systemic disease. Management typically involves three pillars: systemic medication, local wound care, and addressing underlying triggers.

First‑Line Systemic Medications

• Corticosteroids – oral prednisone 0.5–1 mg/kg/day is the most rapid‑acting agent for Sweet’s syndrome and mild‑moderate PG. Taper based on response.
• Colchicine – 1.2–1.8 mg/day useful for recurrent Sweet’s syndrome and subcorneal pustular dermatosis.
• Dapsone – 50–100 mg daily (with baseline G6PD testing) effective for Sweet’s syndrome and erythema elevatum diutinum.

Second‑Line / Steroid‑Sparing Agents

• Cyclosporine – 3–5 mg/kg/day; especially helpful in PG refractory to steroids.
• Azathioprine – 2–2.5 mg/kg/day; considered for chronic disease or when steroids cause side‑effects.
• Mycophenolate mofetil – 1–2 g/day; beneficial in ulcerative‑colitis‑associated PG.
• TNF‑α inhibitors (infliximab, adalimumab, certolizumab) – strong evidence for PG, particularly in IBD‑related cases.
• IL‑1 blockers (anakinra, canakinumab) – emerging data for Sweet’s syndrome and autoinflammatory-associated NDs.

Topical & Local Therapies

• High‑potency topical steroids (clobetasol 0.05 % or betamethasone 0.05 %) for limited Sweet’s lesions.
• Topical tacrolimus 0.1 % for patients who cannot tolerate steroids.
• Local wound care for PG ulcers – non‑adherent dressings, gentle debridement, and negative‑pressure wound therapy in selected cases.

Procedural Options

• Intralesional corticosteroid injection for isolated PG nodules.
• Laser therapy (pulsed dye laser) for erythema elevatum diutinum.

Addressing Underlying Triggers

• Discontinuation of offending drugs (e.g., G‑CSF, ATRA).
• Optimal control of associated diseases – chemotherapy for leukemia, biologics for IBD, disease‑modifying antirheumatic drugs (DMARDs) for arthritis.

Lifestyle & Supportive Measures

• Smoking cessation – improves wound healing and reduces PG recurrence.
• Nutrition optimisation – protein‑rich diet to support skin repair.
• Stress‑management techniques; emotional stress can aggravate autoinflammatory pathways.

Living with Neutrophilic Dermatoses

Managing a chronic or recurrent ND involves daily habits that minimise flare‑ups and enhance quality of life.

Skin‑Care Routine

• Gentle cleansing with pH‑balanced, fragrance‑free cleansers.
• Avoidance of abrasive scrubs or harsh chemicals.
• Moisturise twice daily with a barrier‑repair ointment (e.g., petrolatum or ceramide‑based creams).
• Protect open lesions with non‑adhesive dressings; change dressings at least once daily or when soiled.

Monitoring & Follow‑Up

• Keep a symptom diary – note new lesions, pain scores, fevers, medication changes.
• Regular follow‑up with dermatology (every 3–6 months for stable disease; sooner if flares).
• Lab monitoring: CBC, liver/kidney panels every 2–3 months when on systemic immunosuppressants.

Psychosocial Support

• Connect with patient groups (e.g., Sweet’s Syndrome Support Network, PG Association).
• Consider counseling or cognitive‑behavioral therapy to cope with visible skin lesions.

Practical Tips for Daily Life

• Wear loose, breathable clothing (cotton) to avoid friction.
• When traveling, pack extra dressings, a short course of oral steroids (if prescribed), and a list of emergency contacts.
• Inform healthcare providers (dentists, surgeons) about the pathergy phenomenon; prophylactic steroids may be recommended before procedures.

Prevention

Because many NDs are triggered by systemic disease or medications, “prevention” focuses on risk‑reduction strategies.

• Control underlying illnesses – maintain remission in IBD, adhere to cancer treatment protocols, keep rheumatologic disease quiescent.
• Avoid unnecessary trauma – use soft toothbrushes, refrain from aggressive nail‑cutting, and protect skin during sports.
• Medication vigilance – discuss potential skin reactions before starting G‑CSF, ATRA, or high‑dose retinoids.
• Healthy lifestyle – quit smoking, limit alcohol, maintain a balanced diet, and engage in regular moderate exercise.

Complications

If left untreated or inadequately managed, neutrophilic dermatoses can lead to:

• Severe, expanding ulcers – especially with PG, which may involve deep tissue and bone.
• Secondary bacterial infection – requires antibiotics and may progress to cellulitis or sepsis.
• Permanent scarring and contractures – can limit joint mobility and cause cosmetic concerns.
• Systemic involvement – Sweet’s syndrome can be associated with leukemic transformation; persistent fever may mask sepsis.
• Psychological impact – chronic pain and disfigurement increase risk of depression and anxiety.

When to Seek Emergency Care

---

References:
[1] Mayo Clinic. Sweet’s syndrome (acute febrile neutrophilic dermatosis). https://www.mayoclinic.org/diseases‑conditions/sweets‑syndrome/
[2] Cleveland Clinic. Pyoderma gangrenosum. https://my.clevelandclinic.org/health/diseases/21510-pyoderma‑gangrenosum
[3] National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Neutrophilic dermatoses. https://www.niams.nih.gov/health‑topics/neutrophilic‑dermatoses
[4] WHO. International Classification of Diseases 11th Revision (ICD‑11). https://icd.who.int/
[5] UpToDate. Diagnosis and management of neutrophilic dermatoses. (accessed May 2024).
[6] CDC. Hematologic malignancies and associated skin conditions. https://www.cdc.gov/cancer/hematologic/

```